{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment.","groups":[{"description":"INCB001158 dosed at 50mg BID in combination with epacadostat (100 mg BID) and pembrolizumab (200 mg Q3W)","id":"OG000","title":"INCB001158 50mg BID+ Epacadostat + Pembrolizumab"},{"description":"INCB001158 dosed at 75mg BID in combination with epacadostat (100 mg BID)and pembrolizumab (200 mg Q3W)","id":"OG001","title":"INCB001158 75 mg BID + Epacadostat + Pembrolizumab"}],"populationDescription":"No patients were analyzed due to insufficient numbers and risk of identifying patient by reporting data on 1 person enrolled in cohort 2","reportingStatus":"POSTED","timeFrame":"Up to approximately 12 months per subject","title":"Phase 1 Only: Safety and Tolerability of INCB001158 in Combination With Epacadostat ± Pembrolizumab as Assessed by Number of Participants With a Treatment-emergent Adverse Event (TEAE)","type":"PRIMARY"}